What is NuMedii?
NuMedii is at the forefront of transforming drug discovery and precision therapeutics through the strategic application of big data and artificial intelligence. The company is dedicated to enhancing the efficiency and effectiveness of the drug development pipeline, offering innovative solutions tailored for pharmaceutical companies and researchers. By harnessing advanced technological capabilities, NuMedii aims to significantly disrupt conventional methodologies within the pharmaceutical sector, positioning itself as a key player in the advancement of medical science.
How much funding has NuMedii raised?
NuMedii has raised a total of $3.5M across 1 funding round:
Series A
$3.5M
Series A (2013): $3.5M with participation from Lightspeed Venture Partners, Claremont Creek Ventures, and Life Science Angels
Key Investors in NuMedii
Lightspeed Venture Partners
Lightspeed Venture Partners (lsvp.com) is a global multistage venture capital firm that invests in early and growth-stage technology companies across various sectors, partnering with founders from seed through IPO/M&A.
Claremont Creek Ventures
Claremont Creek Ventures (CCV) is a seed and early-stage venture firm focusing on information technology (IT) driven opportunities, particularly in digital healthcare, energy technology, payments/commerce, and online businesses.
Life Science Angels
Life Science Angels is a leading angel investment group focused on early-stage life science companies, providing investment opportunities and support to entrepreneurs in the sector.
What's next for NuMedii?
The recent major strategic investment in NuMedii, following its Series A financing, indicates a strong market validation and provides the necessary capital for scaling its operations and further developing its AI-driven platform. This infusion of capital is expected to accelerate NuMedii's go-to-market strategy, expand its research and development initiatives, and solidify its position in the competitive landscape of pharmaceutical innovation. The company is poised to leverage this financial backing to forge new partnerships and drive significant advancements in precision therapeutics.
See full NuMedii company page
